Where is Liquidia located?

Liquidia is headquartered in Morrisville, United States.

How many employees does Liquidia have?

As of Aug 31, 2026, the latest employee count at Liquidia is 295.

Is Liquidia a funded company?

Liquidia is a funded company, having raised a total of $90.3M across 14 funding rounds to date. The company's 1st funding round was a $***** Series C round.

When was the latest funding round of Liquidia?

Liquidia's latest funding was a $***** Post IPO round on Apr 13, 2021, with participation from 0 investor.

What is the annual revenue of Liquidia?

Annual revenue of Liquidia is between $100M and $500M as on Dec 31, 2025

Where does Liquidia rank among its competitors?

Liquidia ranks 1st amongst 288 active competitors, of which 79 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was YolTech, which secured $73.7M in May, 2026.

Who are the top competitors of Liquidia?

Liquidia's top competitors include Genedit, Actelion and Aera. Among them, YolTech secured the most recent funding round in May, 2026.

Liquidia - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions. The company uses proprietary PRINT particle engineering technology to develop YUTREPIA inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Key Metrics

Founded Year

2004

Location

Morrisville, United States

Stage

Public

Total Funding

$90.3M in 14 rounds

Latest Funding Round

Post IPO, Apr 13, 2021, $*****

Investors

Canaan & 19 more

Ranked

1^st among 288 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

295 as on Aug 31, 2026

Investment & Acquisitions

Raregen

Similar Companies

Genedit & 369 more

Exit Details

Public

View Liquidia's full profile

Liquidia is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
LIQUIDIA TECHNOLOGIES INC CIN: 1330436 , United States, Active	Jun 07, 2004	$1M - $10M (As on Dec 31, 2019)	-	-
LIQUIDIA CORP CIN: 1819576 , United States, Active	Jun 16, 2020	$100M - $500M (As on Dec 31, 2025)	-	-
LIQUIDIA TECHNOLOGIES, INC CIN: 201926605 , United States, Active		-	164 (As on Dec 31, 2024)	-

Liquidia got listed on Jul 26, 2018.

Click here to take a look at Liquidia's IPO in detail

Liquidia has raised a total funding of $90.3M over 14 rounds. Liquidia has 20 institutional investors.

Here is the list of recent funding rounds of Liquidia:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 13, 2021	7052818	Post IPO	6261704	9007339	7399180	8618638
Jan 07, 2020	9906205	Post IPO	8692903	6191048	1191520	9683505
Feb 20, 2018	9324552	Series D	1199773	6749202	1460041	Amereus & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Liquidia's funding rounds and investors

Liquidia's employee count trend

Liquidia has 295 employees as of Aug 26. Here is Liquidia's employee count trend over the years:

Uncover Liquidia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Liquidia include Genedit, Actelion and Aera. Here is the list of Top 10 competitors of Liquidia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Liquidia 2004, Morrisville (United States), Public	Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions	$90.3M	Canaan, Gates & 18 others	68/100
2nd	Genedit 2016, Berkeley (United States), Series B	Developer of drug delivery system for genetic medicines	$93.5M	IMM Investment, SK & 20 others	65/100
3rd	Actelion 1997, Allschwil (Switzerland), Acquired	Discovery, development, and commercialization of innovative treatments for orphan diseases	$46M	Atlas Venture, NeoMed & 11 others	63/100
4th	Aera 2021, Boston (United States), Series B	Developer of genetic medicines across a wide range of therapeutic areas	$193M	Arch Venture Partners, Google Ventures & 3 others	62/100
5th	NanoSyrinx 2018, Coventry (United Kingdom), Series A	Developer of targeted intracellular delivery platform for biological molecules	$21.6M	Octopus Ventures, M Ventures & 15 others	61/100
6th	Helex 2021, New York City (United States), Seed	Provider of next-generation gene-editing therapies	$6M	pi Ventures, IndieBio & 2 others	59/100
7th	Gossamer Bio 2017, San Diego (United States), Public	Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer	$330M	Hillhouse, Omega Funds & 15 others	57/100
8th	Starpharma 1996, United States, Public	Biotechnology company advancing dendrimer technology for improved patient health outcomes	-	The Australian health system, HHS	57/100
9th	YolTech 2021, Shanghai (China), Series C	Developer of gene editing and LNP delivery platforms for therapeutics	$133M	Decheng Capital, Loayal Valley Capital & 10 others	56/100
10th	Acorda 1995, Ardsley (United States), Acquired	Developer of therapies that restore neurological function	$66.5M	Saints Capital, Abn Amro & 16 others	56/100